Of note, in an obese mouse model that exhibited characteristics of NAFLD, remogliflozin effectively improved ALT and AST levels and reduced hepatic triglyceride content (39). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.